Core Insights - ProMIS Neurosciences, Inc. is participating in the Guggenheim 2 Annual Healthcare Innovation Conference on November 10, 2025, where CEO Neil Warma will engage in a fireside chat and one-on-one investor meetings [1][2] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers linked to neurodegenerative diseases, including Alzheimer's disease (AD) [3] - The company utilizes its proprietary EpiSelect™ platform to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in various neurodegenerative disorders such as AD, ALS, FTD, MSA, and PD [3] Product Development - PMN310 is the lead product candidate for AD, designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [4] - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential for expedited development [4] Clinical Trials - Following positive results from the Phase 1a trial of PMN310, ProMIS initiated the PRECISE-AD Phase 1b clinical trial, which is a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics of multiple ascending doses of PMN310 in patients with Mild Cognitive Impairment and mild AD [5] - The PRECISE-AD trial aims to evaluate the effects of PMN310 on biomarkers associated with AD pathology and clinical outcomes, with a primary focus on safety and reduced risk of ARIA [5] Technology Platform - The EpiSelect platform developed by ProMIS Neurosciences identifies conformational epitopes on toxic misfolded proteins, enabling the generation of selective therapeutic antibodies and vaccines [6] - PMN310 has shown high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing risks associated with targeting vascular amyloid [6]